Skip to content

Soft Tissue Integration of Different Abutment Surfaces

Effect of Argon Plasma Abutment Activation on Soft Tissue Healing: RCT Study With Histological Assessment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05821673
Enrollment
30
Registered
2023-04-20
Start date
2021-06-21
Completion date
2022-06-30
Last updated
2023-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Edentulous Alveolar Ridge, Soft Tissue Healing

Brief summary

Objective of the present study was to assess the peri-implant soft tissue profiles between argon plasma pre-treated (PT) and non-treated (NPT) abutments by comparing clinical and histological parameters 2 months after abutment placement.

Detailed description

Patients that need implant supported restoration were recruited for this study. At baseline a specific abutment was screwed at 20 N.Two months following healing abutment placement clinical measurements were evaluated. Endopoints of the study: Histological outcomes at 2 using traditional histological staining (ematossilin/eosin) Immunohistological outcomes at 2 using different stainings. Postoperative complications. Comparison between the histological outcomes and the preoperative clinical evaluation of the sites

Interventions

PROCEDUREArgon plasma pre-treated abutment insertion

abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.

PROCEDUREabutment insertion

the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment

Sponsors

Studio Odontoiatrico Associato Dr. P. Cicchese e L. Canullo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

the histologist was blinded

Intervention model description

Participants received either abutments with machine surface characterized by circular micro-threads with a furrow of less than 2 um (surface roughness: Ra=0.2 and Sa=0.11) or abutments with rough Ultrathin Threaded Microsurface with a triangular contour tread with a pitch of 50 μm (surface roughness: Ra=0.62 and Sa=0.60) abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. in control group were allocated argon plasma non-treated abutmentsParticipants underwent 2-level randomization for allocation of abutments with different surface configurations and experimental treatment using permuted block technique to limit any selection bias. Allocation concealment was preserved by sealing the tested abutments in sterile envelopes sealed in opaque sleeves opened at the time of the second surgical step.

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

1. Patient requiring implant supported restoration. 2. Residual alveolar bone width of edentulous jaw of \> 8mm. 3. Keratinized mucosa width of \>6mm 4. Males and females between 18-80 years old 5. Patients with healthy periodontal conditions (Treated periodontitis, PI\<25%, BoP\<25%) 6. Patients that are willing to sign an informed consent and participate in a clinical study 7. Generally fit and healthy and able to undergo oral surgical procedures under local anesthesia. 8. Teeth at the surgical site which required removal were extracted a minimum of 12 weeks prior to sinus floor elevation

Exclusion criteria

1. Patients who smoke over 10 cigarettes/day 2. Pregnancy (confirmed by verbal inquiry) 3. Chronic systemic pathologies (e.g. diabetes) and neoplastic of the Oro-Facial District 4. 4. Patients taking bisphosphonates 5. Any sites where an implant already failed sites 6. Untreated Periodontitis 7. Dental sites with acute infections 8. Chronic inflammatory diseases of the oral cavity 9. Autoimmune diseases (cortisone intake) 10. Allergy declared to one or more medicaments to be used during treatment 11. Alcoholics patients and/or drug addicts. 12. History or malignant tumours of the maxillary sinus 13. History of local radiation therapy

Design outcomes

Primary

MeasureTime frameDescription
Histological and immunohistochemical assessment2 months after abutment placementsoft peri-implant tissues and abutment were harvested and histologically processedSpecialized stainings (hematoxylin eosin and picrocirious red) coupled with immunohistochemistry (vimentin, collagen, and CK10) were performed to assess soft tissue inflammation and healing, as well as the collagen content keratinization.
Plaque index (PI)2 months after abutment placementPI scores were recorded in 6 points around each abutment, averaged, and expressed in %. PI was evaluated with a score of 0,1,2, 3 depending on the amount of plaque at each site.
Bleeding on probing (BoP)2 months after abutment placementBoP scores were recorded in 6 points around each abutment, averaged, and expressed in %.BoP was used as a dichotomous variable

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026